Evidence map›Paper›PMID 29066743›Full record

ArticleScientific reports2017

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Simon Body, Anna Esteve-Arenys, Hadjer Miloudi, Clara Recasens-Zorzo, Guergana Tchakarska, Alexandra Moros, Sophie Bustany, Anna Vidal-Crespo, Vanina Rodriguez, Régis Lavigne and 12 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 44 citations in OpenAlex.

  1. The Novel Immunocompetent Eµ-SOX11CCND1 Mouse Model Phenotypically and Molecularly Resembles Human Mantle Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  2. Article
  3. Characterization and molecular targeting of CFIm25 (NUDT21/CPSF5) mRNA using miRNAs.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  4. Article
  5. Mechanisms of the role of proto-oncogene activation in promoting malignant transformation of mature B cells.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Repurposed Effect ofCurrent oncology (Toronto, Ont.) · 2022
    Article
  13. Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Cancers · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 4 countries.

Simon BodyNormandie Univ, INSERM U1245, UNICAEN, UNIROUEN, Caen, Rouen, France.
Anna Esteve-ArenysDivision of Haematology and Oncology, IDIBAPS, Barcelona, Spain.
Hadjer MiloudiNormandie Univ, INSERM U1245, UNICAEN, UNIROUEN, Caen, Rouen, France.
Clara Recasens-ZorzoDivision of Haematology and Oncology, IDIBAPS, Barcelona, Spain.
Guergana TchakarskaNormandie Univ, INSERM U1245, UNICAEN, UNIROUEN, Caen, Rouen, France.
Alexandra MorosDivision of Haematology and Oncology, IDIBAPS, Barcelona, Spain.
Sophie BustanyNormandie Univ, INSERM U1245, UNICAEN, UNIROUEN, Caen, Rouen, France.
Anna Vidal-CrespoDivision of Haematology and Oncology, IDIBAPS, Barcelona, Spain.
Vanina RodriguezDivision of Haematology and Oncology, IDIBAPS, Barcelona, Spain.
Régis LavignePlateforme protéomique - Protim, Biogenouest, Rennes, France.
Emmanuelle ComPlateforme protéomique - Protim, Biogenouest, Rennes, France.
Isolda CasanovaGrup d'Oncogènes i Antitumorals, lnstitut d'Investigacions Biomèdiques Sant Pau and Centro de Investigación Biomédica en Red, Barcelona, Spain.
Ramón ManguesGrup d'Oncogènes i Antitumorals, lnstitut d'Investigacions Biomèdiques Sant Pau and Centro de Investigación Biomédica en Red, Barcelona, Spain.ORCID 0000-0003-2661-9525
Oliver WeigertMedical Department III, University Hospital, Ludwig Maximilians University, Munich, Germany.
Alejandra Sanjuan-PlaHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Pablo MenéndezJosep Carreras Leukaemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Bénédicte MarcqService d'anatomie et cytologie pathologiques, Centre Henri Becquerel, Rouen, France.
Jean-Michel PicquenotNormandie Univ, INSERM U1245, UNICAEN, UNIROUEN, Caen, Rouen, France.
Patricia Pérez-GalánDivision of Haematology and Oncology, IDIBAPS, Barcelona, Spain.
Fabrice JardinNormandie Univ, INSERM U1245, UNICAEN, UNIROUEN, Caen, Rouen, France.
Gaël RouéDivision of Haematology and Oncology, IDIBAPS, Barcelona, Spain.ORCID 0000-0003-0245-2257
Brigitte SolaNormandie Univ, INSERM U1245, UNICAEN, UNIROUEN, Caen, Rouen, France. brigitte.sola@unicaen.fr.
Inserm · FRConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESJosep Carreras Leukaemia Research Institute · ESUniversité de Rennes · FRHospital Universitari i Politècnic La Fe · ESInstitució Catalana de Recerca i Estudis Avançats · ESLaboratoire National Henri Becquerel · FRLudwig-Maximilians-Universität München · DEVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is a hematologic neoplasm characterised by the t(11;14)(q13;q32) translocation leading to aberrant cyclin D1 expression. The cell functions of cyclin D1 depend on its partners and/or subcellular distribution, resulting in different oncogenic properties. We observed the accumulation of cyclin D1 in the cytoplasm of a subset of MCL cell lines and primary cells. In primary cells, this cytoplasmic distribution was correlated with a more frequent blastoid phenotype. We performed immunoprecipitation assays and mass spectrometry on enriched cytosolic fractions from two cell lines. The cyclin D1 interactome was found to include several factors involved in adhesion, migration and invasion. We found that the accumulation of cyclin D1 in the cytoplasm was associated with higher levels of migration and invasiveness. We also showed that MCL cells with high cytoplasmic levels of cyclin D1 engrafted more rapidly into the bone marrow, spleen, and brain in immunodeficient mice. Both migration and invasion processes, both in vivo and in vitro, were counteracted by the exportin 1 inhibitor KPT-330, which retains cyclin D1 in the nucleus. Our data reveal a role of cytoplasmic cyclin D1 in the control of MCL cell migration and invasion, and as a true operator of MCL pathogenesis.

Indexed as

Cell MovementActive Transport, Cell NucleusAdultAgedAged, 80 and overAnimalsCell NucleusCell Transformation, NeoplasticCyclin D1CytoplasmCytosolFemaleHumansLymphoma, Mantle-CellMaleMiceCyclin D1

Identifiers

PMID29066743
PMCPMC5654982
OpenAlexW2765433239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.